PPCB — Propanc Biopharma Income Statement
0.000.00%
Last trade - 00:00- $48.19m
- $49.38m
Annual income statement for Propanc Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | — | — | 2.01 | 1.73 | 1.48 |
| Operating Profit | 0 | 0 | -2.01 | -1.73 | -1.48 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | — | — | -2.71 | -2.79 | -1.95 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | — | — | -2.66 | -2.66 | -1.82 |
| Net Income Before Extraordinary Items | |||||
| Net Income | — | — | -2.66 | -2.66 | -1.82 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | — | — | -2.66 | -3.13 | -2.01 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | — | — | -2,646,710 | -108,796 | -1,446 |